{
    "nct_id": "NCT03830866",
    "official_title": "A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer",
    "inclusion_criteria": "For inclusion in the study, patients should fulfill the following criteria:\n\n1. Female\n2. Aged at least 18 years\n3. Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO (2009) Stages IB2 to IIB node positive or FIGO (2009) IIIA-IVA any node\n4. No prior chemotherapy or radiotherapy for cervical cancer\n5. WHO/ECOG performance status of 0-1\n6. At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion at baseline.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "Patients should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Diagnosis of small cell (neuroendocrine) histology or mucinous adenocarcinoma cervical cancer\n2. Intent to administer a fertility-sparing treatment regimen\n3. Undergone a previous hysterectomy\n4. Evidence of metastatic disease per RECIST 1.1 including lymph nodes â‰¥15 mm (short axis) above the L1 cephalad body, in the inguinal region or outside the planned radiation field.\n5. History of allogeneic organ transplantation\n6. Active or prior documented autoimmune or inflammatory disorders\n7. Uncontrolled intercurrent illness\n8. History of another primary malignancy and active primary immunodeficiency",
    "miscellaneous_criteria": ""
}